RENDA GIULIA

PRESENT POSITION
Associate Professor SSD MEDS-07/B (ex-MED/11) “Cardiovascular Diseases” - Department of Neurosciences, Imaging and Clinical Sciences, Section of Cardiovascular and Pharmacological Sciences – G. d’Annunzio University, Chieti-Pescara


SCIENTIFIC AND PROFESSIONAL BACKGROUND
• 1990: Diploma at High School, Classic Lycée G. B. Vico, Chieti
• 1996: Degree in Medicine, School of Medicine, G. d'Annunzio University, Chieti
• 1997: Italian Board Certification - G. d'Annunzio University, Chieti
• 1998: Italian National Board of Medicine, Board of Chieti (Italy) – Registration n. 3892
• 2001: Postgraduate in Cardiology - Institute of Cardiology, Catholic University of the Sacred Heart, Roma
• 2005: PhD in Biomedical Technologies and Functional Bioimaging - Institute of Cardiology, Department of Neurosciences and Imaging, G. d'Annunzio University, Chieti
• 2005-2008: Post-doctoral research grant - Institute of Cardiology, Department of Neurosciences and Imaging, G. d'Annunzio University, Chieti
• 2008-2009: Second-level Master’s Degree in Pediatric and Developmental Cardiology at the Pediatric Cardiology Unit, Institute of Cardiovascular Diseases, University of Bologna
• 2008-2019: Assistant Professor SSD Med/11 “Cardiovascular Diseases” - Department of Neurosciences, Imaging and Clinical Sciences, Section of Cardiovascular and Pharmacological Sciences – G. d’Annunzio University, Chieti-Pescara
• 2019- present: Associate Professor SSD Med/11 “Cardiovascular Diseases” - Department of Neurosciences, Imaging and Clinical Sciences, Section of Cardiovascular and Pharmacological Sciences – G. d’Annunzio University, Chieti-Pescara
• 2021: National Scientific Qualification for Full Professorship - SSD MEDS-07/B (formerly Med/11) “Cardiovascular Diseases”, SC 06D1


SCIENTIFIC ACTIVITY

From 01-01-1995 to 31-10-1997
Research activity at the Cardiovascular Research Laboratory, Institute of Pharmacology I, University “G. d’Annunzio” of Chieti-Pescara.

Main research areas:
• platelet aggregation
• expression and pharmacological modulation of cyclooxygenases in patients with ischemic heart disease
• clinical pharmacology of antiplatelet drugs

Research period abroad (July – September 1995) at the Institute of Cellular and Molecular Physiopathology of Blood and Vessel Cells, Unit 348 of INSERM (Institut National de la Santé et de la Recherche Médicale), Paris.

From 01-11-1997 to 15-10-2001
Research activity during the Specialization School in Cardiology at the Institute of Cardiology and the Institute of Hemostasis Physiopathology, Catholic University of the Sacred Heart, Rome.

Main research areas:
• platelet aggregation
• antiplatelet activity of glycoprotein IIb/IIIa inhibitors

From 01-11-2001 to present
Research activity at the Experimental Cardiology Laboratory – CAST (Center for Advanced Studies and Technology) – Department of Neurosciences, Imaging and Clinical Sciences – Section of Cardiovascular and Pharmacological Sciences – University “G. d’Annunzio” of Chieti-Pescara

From 01-11-2018 to present
Head of the Experimental Cardiology Laboratory – Unit of Systems Pharmacology and Translational Therapeutics – CAST

Main research areas:
• clinical pharmacology of antiplatelet and anticoagulant drugs
o platelet aggregation and antiplatelet drugs
o resistance to antiplatelet drugs
o interaction between NSAIDs and aspirin in patients with ischemic heart disease
o kinetics of anticoagulant effects of heparins and bleeding complications in patients undergoing coronary artery bypass grafting
o effects of anticoagulant drugs on platelet function
o genetic determinants of response to dabigatran in patients with atrial fibrillation

• antithrombotic prophylaxis in atrial fibrillation
o efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients undergoing cardioversion
o efficacy and safety of NOACs in patients with valvular disease
o relationship between silent atrial fibrillation and cryptogenic stroke
o predictors of atrial fibrillation onset and cardiovascular risk
o efficacy of edoxaban in resolving atrial thrombosis
o response to antithrombotic drugs in obese patients with atrial fibrillation

• blood pressure variability and organ damage
• nutrigenetics of coffee
• cardiovascular outcomes in COVID-19 patients
• hemostasis and thrombosis alterations in dialysis patients
• variability of aspirin response in preeclamptic women
• echocardiographic biomarkers for type 2 myocardial infarction
• role of bacterial microvesicles in atrial fibrosis
• effects of nanoplastics on platelet function

ORGANIZATION, MANAGEMENT AND COORDINATION OF NATIONAL AND INTERNATIONAL RESEARCH GROUPS, OR PARTICIPATION IN THEM

From 2002 to 2011
Research collaboration with the Systems Pharmacology and Translational Therapeutics (SPaTT Lab), formerly Pharmacodynamics and Eicosanoid Pharmacology Unit, at CAST (Center for Advanced Studies and Technology) – Department of Neurosciences, Imaging and Clinical Sciences – Section of Cardiovascular and Pharmacological Sciences – University “G. d’Annunzio” of Chieti-Pescara.
Within this collaboration, the following research lines were developed:
• expression and pharmacological modulation of cyclooxygenases
• interaction between NSAIDs and aspirin in patients with ischemic heart disease

From 2015 to 2017
Collaboration with the TIMI Study Group - Boston, MA (USA)
Within this collaboration, the following research lines were developed:
• efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients undergoing cardioversion
• efficacy and safety of NOACs in patients with valvular disease

From 2015 to 2021
Participation in the Team in AF (Thrombosis ExchAnge prograM): European research group on atrial fibrillation
Within this group, collaboration included overall analyses and multiple sub-analyses of the European atrial fibrillation registries PREFER in AF and PREFER in AF - PROLONGATION

From 2018 to 2020
Collaboration with the Research Group of Malmö Lund University, Malmö, Sweden
Within this collaboration, the following research lines were developed:
• predictors of atrial fibrillation onset and cardiovascular risk
• prognostic significance of non-cardiac syncope

From 2025 to present
Collaboration with the Institute of Cardiovascular Sciences - Translational Research Department (ICCC; Hospital Santa Creu and Sant Pau), Barcelona, Spain
Within this collaboration, the following research line has been undertaken:
• effects of eicosapentaenoic acid ethyl ester on triglyceride-induced dysregulation of the liver–adipose tissue axis and potential implications for cardiovascular events

From 2012 to present
Participation in the Thrombosis Study Group of the Italian Society of Cardiology
Within this group:
• contribution to several review articles and participation in scientific meetings and conferences
• Coordinator of the Thrombosis Study Group (2017–2018)
During the coordination period:
• organization of symposia for the National Congress of the Italian Society of Cardiology (2017 and 2018)
• organization of the II Joint Congress of the Study Groups on Atherosclerosis Pathogenesis and Thrombosis (Modica, June 2018)
• promotion and coordination of review articles

From 2005 to present
Participation in the Working Group on Thrombosis of the European Society of Cardiology

PRINCIPAL INVESTIGATOR OF THE FOLLOWING INTERNATIONAL MULTICENTER CLINICAL TRIALS

• LIBREXIA-ACS: A Phase 3, randomized, double-blind, placebo-controlled, event-driven study to demonstrate the efficacy and safety of Milvexian, an oral Factor XIa inhibitor, after a recent acute coronary syndrome. Principal Investigator of the Chieti Center (ongoing study).
• OCEANIC-AF: A multicenter, international, randomized, active comparator-controlled, double-blind, double-dummy, parallel-group, 2-arm, Phase 3 study comparing the efficacy and safety of the oral FXIa inhibitor Asundexian versus Apixaban for stroke prevention in patients with atrial fibrillation. Principal Investigator of the Chieti Center (completed in 2024).
• PERSEO: PERcutaneouS coronary intErventions in patients treated with oral anticoagulant therapy: the PERSEO Registry. Principal Investigator of the Chieti Center (completed in 2024).
• ETNA-AF: Edoxaban Treatment in Routine Clinical Practice for Patients With Non-Valvular Atrial Fibrillation. Principal Investigator of the Chieti Center (September 1, 2018 – February 2023).
• Italian multicenter study EDO-SP-01-2015: A pilot study on Edoxaban for the resolution of left atrial thrombosis in patients with non-valvular atrial fibrillation. Principal Investigator of the Chieti Center (September 1, 2018 – December 2021).
• GLORIA-AF: Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation. Principal Investigator of the Chieti Center (September 1, 2018 – February 2020).

SUB-INVESTIGATOR IN INTERNATIONAL CLINICAL TRIALS

• 13 international randomized Phase III clinical trials, mainly in the field of antithrombotic treatment in patients with atrial fibrillation or acute coronary syndromes
• 5 international observational clinical trials, mainly in patients with atrial fibrillation or acute coronary syndromes

PARTICIPATION IN NATIONAL AND INTERNATIONAL RESEARCH PROJECTS FUNDED THROUGH COMPETITIVE PEER-REVIEWED CALLS

PRIN (2009): 2009L4X28T_002 – Area 06
Title: Prognostic implications of changes in lymphocyte G-protein coupled receptor kinase-2 levels induced by beta-blocker therapy in patients with heart failure.
Role: Participant. Duration: 24 months. Completed.

BOOST FOR INTERDISCIPLINARY (2022): Project 6700 2022
Title: Variability in low-dose aspirin response in pregnant women at high risk for preeclampsia.
Role: Head of Operational Unit. Duration: 24 months. Funding: €100,000. Completed in 2025.

THE - TUSCANY HEALTH ECOSYSTEM (PNRR) – Project MICROFIBRA
Title: Bacterial microvesicles: implications in atrial fibrillation.
Role: Internal collaborator (WP2). Duration: 12 months. Completed in 2025.
PNRR-MCNT2-2023
Title: Enhanced thrombopoiesis and variability in antiplatelet drug response in acute coronary syndrome patients.
Role: Research collaborator. Duration: 24 months. Funding: €950,000. Ongoing.

RESEARCH FUNDING
• University Research Funds (ex 60%) – Principal Investigator since 2012
• Responsible for industry-sponsored clinical research funds since 2023 (Bayer, Janssen-BMS)

INVITED SPEAKER AT NATIONAL AND INTERNATIONAL CONFERENCES
• Numerous invited lectures at national scientific meetings
• Numerous oral presentations and poster presentations at national and international congresses
• Scientific director of national congresses

AWARDS AND RECOGNITIONS
• August 28, 2007
Thrombosis Young Investigators' Award - ESC Congress 2007
• April 2, 2016
Highest ranking abstract from Italy - ACC Annual Scientific Session 2016
• August 2018
Best Poster Session – ESC Congress 2018

AFFILIATIONS / SCIENTIFIC SOCIETIES
• Italian Society of Cardiology (SIC)
o Member of the Regional Executive Board (Abruzzo-Molise Section), Secretary-Treasurer (2015–2016)
o President-Elect (2017–2018)
o President, Abruzzo-Molise Section (2019–2020 and 2021–2022)
o Member of the Regional Executive Board (2023–2024)
o Member of the Thrombosis Study Group
 Coordinator of the Study Group (2017–2018)
o Fellow of the SIC since December 2023

• Italian Society for the Study of Hemostasis and Thrombosis (SISET)
• Atherosclerosis, Thrombosis and Vascular Biology Study Group (ATBV)
• Italian Society of Pediatric Cardiology (SICP)
• European Society of Cardiology (ESC)
• ESC Working Group on Thrombosis (WG18)

EDITORIAL AND REVIEW ACTIVITY FOR INTERNATIONAL SCIENTIFIC JOURNALS
• Member of the Editorial Board of Frontiers in Cardiovascular Medicine

• Invited reviewer for numerous international scientific journals:
o European Heart Journal
o Journal of the American College of Cardiology
o International Journal of Cardiology
o International Journal of Cardiology - Heart & Vasculature
o Thrombosis and Haemostasis
o European Journal of Clinical Investigation
o Vascular Pharmacology
o Journal of Cardiovascular Medicine
o Journal of Cardiovascular Pharmacology
o Clinical Pharmacology and Therapeutics
o Giornale Italiano di Cardiologia


TEACHING ACTIVITY

DEGREE COURSES
• Lectures and examinations in Cardiovascular Diseases (Integrated Course of Systemic Pathology I), Degree in Medicine and Surgery, University “G. d’Annunzio” of Chieti-Pescara, as Teaching Assistant, from A.Y. 2003/2004 to A.Y. 2011/2012.
• Lecturer in “Cardiology 3” (1 CFU), within Cardiovascular Diseases, Degree in Medicine and Surgery, from A.Y. 2012/2013 to present.
• Lecturer in “Cardiovascular Diseases” (2 CFU), Degree in Cardiovascular Perfusion Techniques, A.Y. 2009/2010 – 2019/2020.
• Lecturer in “Cardiovascular Diseases” (1 CFU), Degree in Healthcare Assistance, A.Y. 2009/2010 – 2019/2020.
o Coordinator of the Integrated Course (2016/2017 – 2019/2020)
• Lecturer in “Hemodynamics and Interventional Cardiology” (3 CFU), from A.Y. 2019/2020 to present
o Coordinator of the Integrated Course (from A.Y. 2019/2020 to present)
• Lecturer in “Cardiovascular Diseases” (2 CFU), Nursing Degree, from A.Y. 2013/2014 to present
o Coordinator of the Integrated Course (from A.Y. 2022/2023 to present)
• Lecturer in “Cardiovascular Diseases” (1 CFU), Radiology Degree, from A.Y. 2020/2021 to present
• Lecturer in “Functional Evaluation in Cardiovascular Diseases” (1 CFU), Physiotherapy Degree, from A.Y. 2023/2024
o Coordinator of the Integrated Course (from A.Y. 2023/2024)
• Elective teaching activities in Cardiovascular Diseases, from A.Y. 2004/2005 to A.Y. 2017/2018
• Member of examination and thesis committees

SPECIALIZATION SCHOOLS
• Lecturer in “Diagnosis of Major Congenital Heart Diseases”, School of Specialization in Cardiovascular Diseases (from A.Y. 2010/2011)
• Lecturer in core disciplines, same School (from A.Y. 2016/2017)
• Lecturer in Cardiovascular Diseases in the following Specialization Schools:
o Vascular Surgery (2014/2015 – 2015/2016)
o Sports Medicine (from 2015/2016)
o Pediatrics (from 2016/2017)
o Nephrology (from 2017/2018)
o Anesthesiology and Intensive Care (from 2017/2018)
o Geriatrics (from 2018/2019)
o Internal Medicine (from 2019/2020)
• Member of examination and specialization thesis committees

MASTER PROGRAMS
• Teaching modules in Palliative Care and Pain Therapy Master (A.Y. 2016/2017 – 2017/2018)
• Teaching module in Pediatric Cardiology (A.Y. 2020/2021)
• Teaching module in management of cardiovascular symptoms (A.Y. 2020/2021)
• Teaching module in chronic cardiovascular disease monitoring (A.Y. 2023/2024)

PHD PROGRAMS
• Member of the PhD Board in “Medical Biotechnology” (2015–2019; from 2020 to present)

TUTORING AND SUPERVISION
• Co-supervisor of 30 MD theses, 15 specialization theses, 1 PhD thesis
• Supervisor of:
o 30 MD theses
o 10 theses in Cardiovascular Perfusion Techniques
o 2 theses in Healthcare Assistance
o 15 specialization theses
• Tutor for medical students and residents in Cardiology
• PhD tutor since 2023

ACADEMIC SERVICE AND ADMINISTRATIVE ACTIVITIES
• Member of admission committees (Medicine, PhD, Specialization Schools)
• Member of research grant and academic recruitment committees
• Member of Department Board (two terms)
• Erasmus delegate for Nursing (since 2019)
• Member of teaching quality and program committees
• Participation in Degree Course Boards and Department Councils

THIRD MISSION ACTIVITIES
• Principal Investigator in international clinical trials
• Participation in funded national research projects
• “Scuole in ritmo” – ECG screening program in primary school children
Early detection of cardiac abnormalities and promotion of prevention culture (ongoing since December 2025)

INTERNATIONALIZATION
• Erasmus delegate: evaluation of agreements, student mobility, supervision of incoming students
• Tutor for Erasmus medical students in Cardiology
• Mobility Programme – ITESHS Project - Addis Ababa, Ethiopia (February 8–13, 2026)
Activities included:
o academic exchange and teaching
o institutional meetings for future collaborations
o interdisciplinary research activities
o healthcare and educational site visits
o development of international partnerships


CLINICAL ACTIVITY

As a Cardiologist, clinical activity is carried out at the Cardiology Unit of SS. Annunziata Hospital:

• From February 2005: clinical activity under research contract
• From December 2008: as University Researcher
• From November 1, 2015: Consultant Cardiologist (National Health Service)

• Responsible for the Pediatric Cardiology Outpatient Clinic (clinical, scientific and teaching activities)